Lv1
65 积分 2021-10-18 加入
Targeting Lung Cancer with Precision: The ADC Therapeutic Revolution
11小时前
已完结
Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study
1个月前
已完结
Treatment advances across the cervical cancer spectrum
2个月前
已完结
Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer
2个月前
已完结
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer
2个月前
已完结
Timing of nivolumab with neoadjuvant carboplatin and paclitaxel for early triple-negative breast cancer (BCT1902/IBCSG 61–20; Neo-N): a non-comparative, open-label, randomised, phase 2 trial
2个月前
已完结
Selective Elimination of Breast Surgery for Invasive Breast Cancer
2个月前
已完结
Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer
2个月前
已完结
Toripalimab plus platinum-doublet chemotherapy as perioperative therapy for initially unresectable NSCLC: An open-label, phase 2 trial
2个月前
已完结
CNS outcomes of osimertinib plus chemotherapy in patients with EGFR mutation positive lung cancer beyond osimertinib progression
3个月前
已关闭
皖公网安备34019202002308
